Aleš Obr1, Vít Procházka2, Andrea Jirkuvová3, Helena Urbánková1, Eva Kriegova4, Petra Schneiderová4, Michaela Vatolíková1, Tomáš Papajík1. 1. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic. 2. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic. Electronic address: vit.prochazka@fnol.cz. 3. Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic. 4. Department of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
Abstract
BACKGROUND: TP53 mutation (TP53mut) and a complex karyotype (CK) were shown to be predictors of poor outcome in mantle-cell lymphoma (MCL). In this study we examined the combined effect of both of these risk factors. PATIENTS AND METHODS: Patients diagnosed with MCL between January 2000 and December 2014 (n = 74) were evaluated. Forty-eight of them had available material for TP53 and cytogenetic examination. We analyzed the prognostic effect of combined TP53mut and CK in the cohort of patients treated with rituximab-containing therapy. RESULTS: Three-year (3-y) overall survival (OS) and 3-y progression-free survival (PFS) in CK patients were shorter compared with non-CK (P = .001 for OS; P = .02 for PFS). TP53mut was a predictor of shorter survival compared with TP53 wild type (OS and PFS; P < .001). The incidence of TP53mut was not significantly associated with CK (P = .240). CK and TP53mut were predictors of inferior PFS and OS independent of age and Mantle-Cell Lymphoma International Prognostic Index, with hazard ratios of 2.35 (P = .024), 4.50 (P < .001) for PFS and 4.31 (P < .001), 5.46 (P < .001) for OS analysis in the CK and TP53mut groups, respectively. The combination of TP53mut and CK status stratified the patients into 3 prognostic groups (P < .001) with the worst outcome in patients with CK and TP53mut. CONCLUSION: TP53 mutation and CK occurred independently and patients harboring both had a dismal prognosis. The study suggests the importance of molecular cytogenetics and examination of the TP53mut status to be performed simultaneously before treatment.
BACKGROUND:TP53 mutation (TP53mut) and a complex karyotype (CK) were shown to be predictors of poor outcome in mantle-cell lymphoma (MCL). In this study we examined the combined effect of both of these risk factors. PATIENTS AND METHODS: Patients diagnosed with MCL between January 2000 and December 2014 (n = 74) were evaluated. Forty-eight of them had available material for TP53 and cytogenetic examination. We analyzed the prognostic effect of combined TP53mut and CK in the cohort of patients treated with rituximab-containing therapy. RESULTS: Three-year (3-y) overall survival (OS) and 3-y progression-free survival (PFS) in CKpatients were shorter compared with non-CK (P = .001 for OS; P = .02 for PFS). TP53mut was a predictor of shorter survival compared with TP53 wild type (OS and PFS; P < .001). The incidence of TP53mut was not significantly associated with CK (P = .240). CK and TP53mut were predictors of inferior PFS and OS independent of age and Mantle-Cell Lymphoma International Prognostic Index, with hazard ratios of 2.35 (P = .024), 4.50 (P < .001) for PFS and 4.31 (P < .001), 5.46 (P < .001) for OS analysis in the CK and TP53mut groups, respectively. The combination of TP53mut and CK status stratified the patients into 3 prognostic groups (P < .001) with the worst outcome in patients with CK and TP53mut. CONCLUSION:TP53 mutation and CK occurred independently and patients harboring both had a dismal prognosis. The study suggests the importance of molecular cytogenetics and examination of the TP53mut status to be performed simultaneously before treatment.
Authors: Martina Doubkova; Eva Kriegova; Simona Littnerova; Petra Schneiderova; Martina Sterclova; Vladimir Bartos; Martina Plackova; Monika Zurkova; Radka Bittenglova; Vladimira Lostaková; Lenka Siskova; Pavlina Lisa; Hana Suldova; Michael Doubek; Jana Psikalova; Tomas Snizek; Pavlina Musilova; Martina Vasakova Journal: Ther Adv Respir Dis Date: 2021 Jan-Dec Impact factor: 4.031
Authors: F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse Journal: Leukemia Date: 2022-04-16 Impact factor: 12.883
Authors: Zuzana Mikulkova; Gayane Manukyan; Peter Turcsanyi; Milos Kudelka; Renata Urbanova; Jakub Savara; Eliska Ochodkova; Yvona Brychtova; Jan Molinsky; Martin Simkovic; David Starostka; Jan Novak; Ondrej Janca; Martin Dihel; Pavlina Ryznerova; Lekaa Mohammad; Tomas Papajik; Eva Kriegova Journal: Sci Rep Date: 2021-01-11 Impact factor: 4.379
Authors: Eva Kriegova; Regina Fillerova; Jiri Minarik; Jakub Savara; Jirina Manakova; Anna Petrackova; Martin Dihel; Jana Balcarkova; Petra Krhovska; Tomas Pika; Petr Gajdos; Marek Behalek; Michal Vasinek; Tomas Papajik Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379
Authors: Diana Malarikova; Adela Berkova; Ales Obr; Petra Blahovcova; Michael Svaton; Kristina Forsterova; Eva Kriegova; Eva Prihodova; Lenka Pavlistova; Anna Petrackova; Zuzana Zemanova; Marek Trneny; Pavel Klener Journal: Cancers (Basel) Date: 2020-07-31 Impact factor: 6.639